Oflocet (Ofloxacin)

Ofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA supercoiling and replication. By binding to these targets, it prevents bacterial DNA synthesis, leading to bacterial cell death. This mechanism provides a bactericidal effect against a broad spectrum of Gram‑negative and Gram‑positive bacteria.

The dosage of Oflocet is individualized by the prescribing clinician based on the infection being treated, patient age, weight, renal function, and local resistance patterns. Healthcare professionals determine the appropriate strength, frequency, and duration of therapy to ensure optimal efficacy and safety.

The safety of Ofloxacin in pregnancy or while nursing has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider after careful consideration.

To request Oflocet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Oflocet (Ofloxacin) shares the class‑wide mechanism of DNA gyrase inhibition with other fluoroquinolones, offering similar broad‑spectrum activity. Compared with agents like ciprofloxacin, Ofloxacin may have a slightly different pharmacokinetic profile, but clinical choice depends on local resistance patterns, patient tolerance, and prescriber preference.

Oflocet should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions preserves drug stability and potency throughout its shelf life.

Oflocet is taken orally, usually with a full glass of water. It may be taken with or without food, but patients should avoid concurrent intake of antacids containing aluminum or magnesium, which can reduce absorption. The exact administration schedule is set by the prescriber.

Serious adverse events linked to Ofloxacin include tendon rupture (especially Achilles), peripheral neuropathy, QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they experience any of these symptoms.

Oflocet is contraindicated in individuals with a known hypersensitivity to Ofloxacin or other fluoroquinolones, patients with a history of tendon disorders related to fluoroquinolone use, and those with documented QT prolongation or significant cardiac arrhythmias. It should also be avoided in patients receiving certain interacting medications without proper monitoring.